Back HCV Populations Children & Adolescents

EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir

Almost all children age 6 to 11 with hepatitis C who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver damage even at that young age, according to a presentation at the at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

FDA Approves Harvoni and Sovaldi for Adolescents with Hepatitis C

The U.S. Food and Drug Administration (FDA) on April 7 approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents age 12 to 17 years. Sofosbuvir/ledipasvir (Harvoni) is now indicated for adolescents with HCV genotypes 1, 4, 5, or 6, while sofosbuvir (Sovaldi) plus ribavirin is approved for those with genotypes 2 or 3.

alt

Read more:

Sofosbuvir + Ribavirin To Be Studied in Children and Adolescents with Hepatitis C

A Phase 2 clinical trial is now underway to evaluate sofosbuvir (Sovaldi) plus ribavirin for children and adolescents, ages 3-17 years, with hepatitis C virus genotypes 2 or 3. Another study will follow to test the forthcoming sofosbuvir/ledipasir coformulation in pediatric patients.

alt

Read more: